النرويج - النرويجية - Statens legemiddelverk

novartis norge (2) - oktreotidacetat - pulver og væske til injeksjonsvæske, suspensjon - 30 mg

النرويج - النرويجية - Statens legemiddelverk

orion corporation - espoo - spironolakton - tablett - 50 mg

النرويج - النرويجية - Statens legemiddelverk

orion corporation - espoo - spironolakton - tablett - 25 mg

النرويج - النرويجية - Statens legemiddelverk

orion corporation - espoo - spironolakton - tablett - 100 mg

النرويج - النرويجية - Statens legemiddelverk

teva sweden ab - takrolimus - kapsel, hard - 5 mg

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinant vesicular stomatitis virus (belastning indiana) med en sletting av konvolutten glykoprotein, erstattet med zaire ebolavirus (belastning kikwit 1995) overflate glykoprotein - hemoragisk feber, ebola - vaksiner - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. bruk av ervebo skal være i samsvar med offisielle anbefalinger.

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

diurnal europe b.v. - hydrokortison - adrenal hyperplasia, congenital - kortikosteroider for systemisk bruk - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.

النرويج - النرويجية - Statens legemiddelverk

abacus medicine a/s - everolimus - tablett - 2.5 mg

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

الاتحاد الأوروبي - النرويجية - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaksiner - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.